UPDATE: Morgan Stanley Maintains Equal-Weight On Regeneron, Raises Target To $387 As Firm Notes 'Eylea outperformed and cost control continued in the JV improving profitability. Pipeline updates from NSCLC, bispecifics and C5 were encouraging'

Do you like seeing these details as to why an analyst recommended a stock? What could we do to make this product better? Let us know by emailing newsdesk@benzinga.com

Benzinga · 11/06/2019 17:07